PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8(+) T-cell Function

Although checkpoint inhibitors that block CTLA-4 and PD-1 have improved cancer immunotherapies, targeting additional checkpoint receptors may be required to broaden patient response to immunotherapy. PVRIG is a coinhibitory receptor of the DNAM/TIGIT/CD96 nectin family that binds to PVRL2. We report...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Immunol Res
Egile Nagusiak: Whelan, Sarah, Ophir, Eran, Kotturi, Maya F., Levy, Ofer, Ganguly, Sudipto, Leung, Ling, Vaknin, Ilan, Kumar, Sandeep, Dassa, Liat, Hansen, Kyle, Bernados, David, Murter, Benjamin, Soni, Abha, Taube, Janis M., Fader, Amanda Nickles, Wang, Tian-Li, Shih, Ie-Ming, White, Mark, Pardoll, Drew M., Liang, Spencer C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7001734/
https://ncbi.nlm.nih.gov/pubmed/30659054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0442
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak